P+P advised Medigene AG on the acquisition of Trianta Immunotherapies GmbH

January 2014

The publicly listed biotechnology company Medigene AG has acquired Trianta Immunotherapies GmbH, a spin-off of the Helmholtz Center in Munich. The acquisition was carried out with a capital increase in return for contributions in kind through partial utilization of authorized capital, excluding the subscription rights of the shareholders of Medigene AG. The former Trianta shareholders will have approximately 9% participation in Medigene AG's share capital after execution of the capital increase. Upon accomplishment of certain milestones, former Trianta shareholders will receive further payments.

Trianta has developed three different immunotherapy platforms for the treatment of various forms of cancer. The managing director of Trianta, Prof. Dr. Dolores Schendel, head of the Institute for Molecular Immunology at the Helmholz Center, will take over the position of Director of Research and Development and fortifies the Helmholtz Center with her team of 15 immunotherapy specialists.

The publicly listed Medigene AG (Frankfurt, Prime Standard), with its company headquarters in Martinsried near Munich, concentrates on clinical research and development of innovative medications for cancer and autoimmune diseases. Medigene is the first German biotechnology company to receive proceeds from a marketed medication that is distributed by partner companies. Medigene has two medication candidates in clinical studies and is developing an innovative immunization technology.

P+P partners Michael Inhester (M&A) und Eva Nase (lead, corporate) advised Medigene, supported by counsel Bernd Graßl and associate Philipp Opitz (both Corporate/M&A).